Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Editas Medicine Inc. EDIT, -4.10% rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a Phase 1/2 clinical trial assessing its experimental treatment for sickle-cell disease. Editas said the therapy was well-tolerated.

Editas shares jump 9% on positive news from sickle-cell study

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

The biotech's shares plummeted after it paused a key clinical trial.

Why Shares of Editas Medicine Dropped 15.5% in November

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of EDIT-301, under development for the treatment of severe sickle cell disease. The clinical data will include safety data from the first two patients and efficacy data from the first patient treated with EDIT-301.

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing

The company could continue lagging the market for a while.

Where Will Editas Medicine Be in 1 Year?

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

The company shelved a clinical trial for one of its lead therapies.

Why Editas Medicine's Shares Are Falling Thursday

EDIT-101 demonstrates a favorable safety profile across all dose cohorts

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

Editas Medicine, Inc. (NASDAQ:EDIT ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Mark Shearman - Chief Scientific Officer Michelle Robertson - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Greg Harrison - Bank of America Joon Lee - Truist Securities Dae Gon Ha - Stifel Phil Nadeau - Cowen & Co. Jay Olson - Oppenheimer Joel Beatty - Baird Yanan Zhu - Wells Fargo Securities Liisa Bayko - Evercore ISI Operator Good morning and welcome to Editas Medicine's Third Quarter 2022 Conference Call. All participants are now in a listen-only mode.

Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

The average of price targets set by Wall Street analysts indicates a potential upside of 138.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to Trade

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2022.

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

Beam Therapeutics

CRISPR Therapeutics

Sarepta Therapeutics

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 10:30 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Mark Shearman - Executive Vice President and Chief Scientific Officer Baisong Mei - Senior Vice President and Chief Medical Officer Michelle Robertson - Chief Financial Officer Conference Call Participants Matthew Harrison - Morgan Stanley & Co. Matthew Harrison Great. Well, good morning everybody.

Editas Medicine, Inc. (EDIT) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference Call Transcript

Amarin Corporation Plc

Sorrento Therapeutics Inc

The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.

3 Biotech Stocks Gaining Momentum

Editas Medicine, Inc. (NASDAQ:EDIT ) 2022 Wells Fargo Healthcare Conference September 7, 2022 1:55 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Mark Shearman - Chief Scientific Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Hi, everyone. Thanks for joining us.

Editas Medicine, Inc. (EDIT) Presents at 2022 Wells Fargo Healthcare Conference (Transcript)

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Why Is Editas (EDIT) Down 19.5% Since Last Earnings Report?

Results from phase 1/2 BRILLIANCE study using EDIT-101 (Cas9 nuclease) for the treatment of patients with Leber Congenital Amaurosis 10 expected 2nd half of 2022. Results from the phase 1/2 RUBY study using EDIT-301 (AsCas12a nuclease) for the treatment of patients with sickle cell disease are expected by end of 2022.

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Editas (EDIT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Alkermes

GlaxoSmithKline

Immunovant Inc

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Editas Medicine Stock (EDIT)